In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies

Huhtala, Tuulia; Laakkonen, Pirjo; Sallinen, Hanna; Ylä‐Herttuala, Seppo; Närvänen, Ale

doi:10.1016/j.nucmedbio.2010.03.001

Cited by 19 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even it emits Auger and internal conversion electrons with low energy that might be interesting for therapeutic approaches [94], primarily γ radiation is used for diagnostic imaging. 111 In-labeled mAb conjugates with the chelators DOTA or DTPA have been investigated in small animals [85,95,96] and human [97,98]. …”

Section: Radiolabeled Cetuximabmentioning

confidence: 99%

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

et al. 2014

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody cetuximab has been approved alone or in combination with: (a) chemotherapy for treatment of colorectal and head and neck squamous cell carcinoma and (b) with external radiotherapy for treatment of head and neck squamous cell carcinoma. The conjugation of radionuclides to cetuximab in combination with the specific targeting properties of this antibody might increase its therapeutic efficiency. This review article gives an overview of the preclinical studies that have been performed with radiolabeled cetuximab for imaging and/or treatment of different tumor models. A particularly promising approach seems to be the treatment with therapeutic radionuclide-labeled cetuximab in combination with external radiotherapy. Present data support an important impact of the tumor micromilieu on treatment response that needs to be further validated in patients. Another important challenge is the reduction of nonspecific uptake of the radioactive substance in metabolic organs like liver and radiosensitive organs like bone marrow and kidneys. Overall, the integration of diagnosis, treatment and monitoring as a theranostic approach appears to be a promising strategy for improvement of individualized cancer treatment.

show abstract

Section: Radiolabeled Cetuximabmentioning

confidence: 99%

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…PET has become very widely used in clinical applications, namely in the assessment of metabolic activity in tumors with 18 F-fluorodeoxyglucose ( 18 F-FDG). Common PET radionuclides include 11 C (t 1/2 = 20.3 min), 18 F (t 1/2 = 110 min), 64 Cu (t 1/2 = 12.7 hr), 68 Ga (t 1/2 = 67.7 min), 86 Y (t 1/2 = 14.7 hr), and 89 Zr (t 1/2 = 78.4 hr). A PET radionuclide decays by emitting a positron (β + ), which then collides with an electron in an annihilation event.…”

Section: B Pet and Spect Imagingmentioning

confidence: 99%

“…85 In 2010, Huhtala et al reported the preparation of 111 In-DTPA-cetuximab. 86 The incorporation of 111 In into the chelate took much less time than that of 64 Cu, with a specific activity of 2.2 GBq/μmol being obtained after a synthesis time of 1 hr. In SKOV-3m cells, accumulation in tumor was seen by SPECT/CT at 24 hr p.i.…”

Section: Cetuximabmentioning

confidence: 99%

Imaging EGFR and HER2 by PET and SPECT: A Review

Corcoran

Hanson

2013

Medicinal Research Reviews

View full text Add to dashboard Cite

In an effort to discover a noninvasive method for predicting which cancer patients will benefit from therapy targeting the EGFR and HER2 proteins, a large body of the research has been conducted toward the development of PET and SPECT imaging agents, which selectively target these receptors. We provide a general overview of the advances made toward imaging EGFR and HER2, detailing the investigation of PET and SPECT imaging agents ranging in size from small molecules to monoclonal antibodies.

show abstract

“…Most of the antibodies are excreted through the liver. Signal in the lower part of the body indicates antibody's accumulation in the tumor area and the upper signal represents remote activation of VEGFR-3 in metastatic lymph nodes (Huhtala et al 2010). …”

Section: Ctmentioning

confidence: 99%

“…Same antibody has been studied as versatile SPECT and PET imaging agent in several cancer models, e.g. malignant mesothelioma, prostate cancer, head-and-neck squamous cell carcinoma, ovarian carcinoma (Figure 2.), colon cancer and universally EGFR positive tumors (Nayak et al 2011, Malmberg et al 2011, Hoeben et al 2011, Huhtala et al 2010, Cho et al 2010, Ping Li et al 2008.…”

Section: Proteinsmentioning

confidence: 99%

Small Animal Imaging in Development of New Generation Diagnostic and Therapeutic Agents

Huhtala¹,

Närvänen²

2012

Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies

Cited by 19 publications

References 18 publications

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy

Imaging EGFR and HER2 by PET and SPECT: A Review

Small Animal Imaging in Development of New Generation Diagnostic and Therapeutic Agents

Contact Info

Product

Resources

About